DCPH Stock Recent News

Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.

Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.80 per share a year ago.

Last year, Deciphera Pharmaceuticals, Inc. was almost destroyed by a trial failure. This year, Deciphera Pharmaceuticals has demonstrated huge benefit in a subpopulation, and also progressed the rest of its pipeline.

Deciphera has a strong portfolio of investigational kinase inhibitors, including ripretinib, vimseltinib, and DCC-3116, that have demonstrated encouraging preliminary efficacy and safety data in treating various types of cancer. The company has completed enrollment in the pivotal Phase 3 MOTION study of vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT), with top-line results expected in Q4 2023.

Deciphera focuses on oncology therapies. The company's lead therapy is Qinlock, approved to treat patients with gastrointestinal stromal tumors.

Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants Jen Larson – Senior Vice President-Finance and Investor Relations Steve Hoerter – President and Chief Executive Officer Dan Martin – Chief Commercial Officer Matt Sherman – Chief Medical Officer Margarida Duarte – Head-International Tucker Kelly – Chief Financial Officer Conference Call Participants Daniel Wolle – JPMorgan Paul Jeng – Guggenheim Tyler Van Buren – Cowen Eun Yang – Jefferies Nicole Gabreski – Piper Sandler Brad Canino – Stifel Peter Lawson – Barclays Operator Good morning, everyone, and welcome to Deciphera Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time all participants are in a listen-only mode.

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -5.26% and 2.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.